Lupin appoints a Chief Corporate Development Officer, plus the pharma companies hiring Alzheimer's and HIV experts in this week's column.
Lupin, the Indian generics and branded pharmaceutical company, has made Theresa Stevens Chief Corporate Development Officer. She will be responsible for worldwide operations including global mergers and acquisitions and “specialty” business strategy. She moves from the same position at Aptalis Pharma, where she oversaw mergers and acquisitions, strategy and global business development. She previously held senior positions for nine years at Novartis.
As well as drug development, Lupin produces active pharmaceutical ingredients (APIs). The company bought last month Mexican drugmaker Grin as a “bridgehead” to generics and API growth in the region.
Copyright - Unless otherwise stated all contents of this web site are © 2015 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
in-Pharmatechnologist.com takes a look at the People on the Move this week.
The WHO Executive Board prepares for a special Ebola meeting, CEO leaves troubled biotech, and senior staff...
Novartis's CEO becomes President of EFPIA, a new head of R&D for Genentech, and more People on...